Active, not recruitingPhase 3NCT01169337
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Studying Light chain deposition disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Sagar Lonial, M.DECOG-ACRIN Cancer Research Group
- Intervention
- Clinical Observation(other)
- Enrollment
- 226 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2026
Study locations (30)
- Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
- Alaska Women's Cancer Care, Anchorage, Alaska, United States
- Anchorage Oncology Centre, Anchorage, Alaska, United States
- Katmai Oncology Group, Anchorage, Alaska, United States
- Providence Alaska Medical Center, Anchorage, Alaska, United States
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- Sutter Auburn Faith Hospital, Auburn, California, United States
- Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
- Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
- Mills-Peninsula Medical Center, Burlingame, California, United States
- Saint Jude Medical Center, Fullerton, California, United States
- Memorial Medical Center, Modesto, California, United States
- Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States
- Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01169337 on ClinicalTrials.gov